Bridging technology and medicine: artificial intelligence in targeted anticancer drug delivery

Abstract

The integration of artificial intelligence (AI) in targeted anticancer drug delivery represents a significant advancement in oncology, offering innovative solutions to enhance the precision and effectiveness of cancer treatments. This review explores the various AI methodologies that are transforming the landscape of targeted drug delivery systems. By leveraging machine learning algorithms, researchers can analyze extensive datasets, including genomic, proteomic, and clinical data, to identify patient-specific factors that influence therapeutic responses. Supervised learning techniques, such as support vector machines and random forests, enable the classification of cancer types and the prediction of treatment outcomes based on historical data. Deep learning approaches, particularly convolutional neural networks, facilitate improved tumor detection and characterization through advanced imaging analysis. Moreover, reinforcement learning optimizes treatment protocols by dynamically adjusting drug dosages and administration schedules based on real-time patient responses. The convergence of AI and targeted anticancer drug delivery holds the promise of advancing cancer therapy by providing tailored treatment strategies that enhance efficacy while minimizing side effects. By improving the understanding of tumor biology and patient variability, AI-driven methods can facilitate the transition from traditional treatment paradigms to more personalized and effective cancer care. This review discusses the challenges and limitations of implementing AI in targeted anticancer drug delivery, including data quality, interpretability of AI models, and the need for robust validation in clinical settings.